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Hepatic resection (HR) and liver transplantation (LT) are surgical treatment options for hepatocellular carcinoma (HCC). However,
it is clinically impossible to perform a randomized, controlled study to determine the usefulness of these treatments. The present
study compared survival rates and recurrence rates of HR versus living donor LT (LDLT) for HCC by using the propensity score
method. Between January 1999 and August 2012, 936 patients (732 HR, 204 LDLT) underwent surgical therapy for HCC in our
center. Using the propensity score matching, 80 well-balanced patients were defined. The 1- and 5-year overall survival rates were
90% and 53% in the HR group and 82% and 63% in the LT group, respectively.They were not significantly different between the two
groups. The odds ratio estimated using the propensity score matching analysis was 0.842 (𝑃 = 0.613). The 1- and 5-year recurrence
rates were significantly lower in the LT group (9% and 21%) than in the HR group (43% and 74%) (𝑃 < 0.001), and the odds ratio
was 0.214 (𝑃 = 0.001). In conclusion, HR should be considered a valid alternative to LDLT taking into consideration the risk for
the living donor based on the results of this propensity score-matching study.
1. Introduction
Hepatocellular carcinoma (HCC) is one of themost common
malignant tumors and is the third frequent cause of cancer-
related death in the world [1]. Surgical treatments including
liver transplantation (LT) and hepatic resection (HR), as well
as medical treatments such as radiofrequency ablation (RFA)
and transarterial chemoembolization (TACE), are widely
performed for the treatment of HCC. In the Barcelona Clinic
Liver Cancer staging and treatment strategy updated in 2011,
HR is recommended for the treatment of single HCC < 3 cm,
Child-Pugh A and B with performance status 0, and normal
portal pressure/bilirubin [2]. LT is recommended for the
treatment of very early (single HCC < 2 cm) and early
stages (single HCC or 3 nodules < 3 cm with performance
status 0) in patients with increased portal pressure/bilirubin
and without associated diseases [2]. The Japanese treatment
algorithm for HCC recommendsHR for Child-Pugh A and B
patients with 3 or few tumors irrespective of tumor size [3]. In
contrast, LT is recommended for Child-Pugh C patients
within the Milan criteria.
In the clinical setting, however, the indications for HR
and LT are not definitely separated or defined. For example,
not a few transplant centers in the world use expanded trans-
plantation criteria forHCCbeyond theMilan criteria, includ-
ing the University of California San Francisco criteria, Kyoto
criteria, and Tokyo criteria [4–9]. Regarding liver function,
LT is sometimes performed for Child-Pugh A and B patients
who cannot undergo HR or RFA due to liver dysfunction or
tumor location. As for type of LT, especially in Japan, living
donor LT (LDLT) is usually performed for such patients
in whom HR or RFA is not indicated due to the shortage
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Table 1: Baseline characteristics of all patients who underwent HR and LDLT.
Characteristic LT (𝑛 = 204) HR (𝑛 = 732) 𝑃 value
Age (years) 57 (22–69)∗ 67 (20–90) <0.001
Sex (male/female) 140/64 576/156 0.004
Child-Pugh classification (A/B/C) 30/78/96 675/55/2 <0.001
DCP (mAU/mL) 50 (5–20600)∗ 164 (6–355000)∗ 0.002
AFP (ng/mL) 33 (0.9–212220)∗ 21.9 (0.9–360093)∗ 0.660
Maximum tumor size (cm) 4.5 (0.5–10.0) 4.0 (0.7–25.0) <0.001
Number of tumors 2 (1–186)∗ 1 (1–15)∗ <0.001
∗Data are given as median (range).
Tumor characteristics are those found on the preoperative imaging.
DCP, des-gamma-carboxy prothrombin; AFP, alpha-fetoprotein.
of deceased donors. Therefore, a comparison of outcomes
after these surgical therapies is needed to validate the above
algorithms and our clinical decision-making. However, there
has been no study to compare outcomes between well-
matched groups after LDLT and HR for HCC.
It is clinically impossible to perform a randomized,
controlled trial to compare the usefulness of LDLT and HR
forHCC. In the present study, therefore, outcomes after LDLT
or HR for HCCwere retrospectively examined in the country
where LDLT is mainstream. The technique of propensity
score computer-matching of preoperative risk factors was
used to obtain a valid comparison between the 2 surgical
treatment groups in all patients and in patients within our
expanded LT criteria for HCC incorporating biomarker for
HCC.
2. Patients and Methods
2.1. Study Patients. A total of 732 patients and 204 patients
underwent HR and LDLT, respectively, for HCC at Kyoto
University Hospital between January 1999 and August 2012
(Table 1). Patients with vascular invasion on preoperative
imaging, including computed tomography (CT) and mag-
netic resonance imaging (MRI), distant metastasis, and
Child-Pugh classification C and those who lacking data for
tumor markers such as alpha-fetoprotein (AFP) and des-
gamma-carboxy prothrombin (DCP) and exact preoperative
tumor size or number were excluded. The remaining 735
patients (107 patients who underwent LT and 628 patients
who underwent HR) were included in this study. We also
defined the 415 patients with our new expanded criteria for
LT for HCC (the Kyoto criteria). Patient records/information
was anonymized and deidentified prior to analysis. The
study was approved by the Ethics Committee of Kyoto
University and conducted in accordance with theDeclaration
of Helsinki of 1996.
2.2. Surgical Procedures, Surgical Indications, and Postopera-
tive Follow-Up for Hepatic Resection. Among the 732 patients
who underwent HR, the surgical procedures consisted of 287
partial resections, 63 segmentectomies, 143 sectionectomies,
220 bisectionectomies, and 19 trisectionectomies. Segments
were defined according to Couinaud’s classification system
[10].The indications for liver resection were based on platelet
count, total bilirubin level, prothrombin time, CT volumetry,
and the indocyanine green Krem index (ICGkrem), which is
calculated by multiplying the ICG disappearance rate by the
ratio of remnant liver volume to the total liver volume, using
an ICGkrem of 0.03 as the lower limit for surgery. In cases
of ICGkrem < 0.03, the results of liver scintigraphy using
technetium-99m-labeled asialoglycoprotein analog were also
considered. Following discharge from hospital, the patients
underwent clinical follow-up (including a blood test and CT
scan) every 3 months. When abnormal data were obtained or
suspected lesionswere detected, further examinations includ-
ing contrast ultrasonography, MRI, or positron emission
tomography were performed.
2.3. Surgical Procedures, Indications, and Immunosuppressive
Treatments for LT. As for LT, the selection criteria for the
recipients, as well as the surgical techniques for the donor
and recipient, have been described in detail elsewhere [11–
13]. Until December 2006, our primary institutional selection
criteria for LDLT for HCC included any size or number of
tumors, provided that there was no distantmetastasis or gross
vascular involvement on preoperative imaging. Since January
2007, we have been using the Kyoto criteria as described else-
where [9]. Briefly, risk factors for recurrence were analyzed
in 136 patients who underwent LT for HCC until December
2006. Based on the results of this study, we established the
Kyoto criteria combining three independent significant risk
factors for recurrence, including tumor number and tumor
size based on the findings of pretransplant imaging and tumor
markers: tumor number ≤ 10, maximal diameter of each
tumor ≤ 5 cm, and serum DCP levels ≤ 400mAU/mL. DCP,
also known as protein induced by vitamin K absence or
antagonist II, is a well-known tumor marker of HCC whose
expression is significantly correlatedwith poor prognosis [14–
17].
Orthotopic LDLTwas performed using a left lobe graft for
24 patients and a right lobe graft for 180 patients. Preoperative
imaging showed that 124 patients met the Milan criteria and
80 did not meet the Milan criteria, and 154 patients met the
Kyoto criteria and 50 did not meet the Kyoto criteria. Preop-
erative measurement of serum DCP and AFP levels has been
described in detail elsewhere [18].
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Table 2: Baseline characteristics of the two propensity-matched groups in all patients.
Characteristic LT (𝑛 = 40) HR (𝑛 = 40) 𝑃 value
Age (years) 60 (23–69)∗ 58 (31–69) 0.671
Sex (male/female) 29/11 29/11 1.000
Underlying liver disease 0.784
Viral hepatitis C 24 22
Viral hepatitis B 12 12
Others 4 6
Child-Pugh classification (A/B) 19/21 19/21 1.000
DCP (mAU/mL) 37 (5–6740)∗ 55.5 (9–51286)∗ 0.120
AFP (ng/mL) 34.1 (0.9–3284)∗ 35.4 (1.7–107579)∗ 0.301
Maximum tumor size (cm) 3.1 (1.0–12.0) 3.4 (0.7–14.5) 0.638
Number of tumors 2 (1–100)∗ 1 (1–15)∗ 0.250
Milan criteria met 22 (55%) 26 (65%) 0.361
Postoperative mortality 6 (15%) 2 (5%) 0.136
∗Data are given as median (range).
Tumor characteristics are those found on the preoperative imaging.
DCP, des-gamma-carboxy prothrombin; AFP, alpha-fetoprotein.
Postoperative mortality means postoperative death within 90 days after surgery in this analysis.
The standard immunosuppression protocol consisted of
tacrolimus and low-dose steroid [19, 20]. No patients were
switched to mammalian target of rapamycin inhibitor.
2.4. Statistical Analysis. We conducted the statistical analysis
for all the defined patients (𝑛 = 735) and subgroup patients
with Kyoto criteria (𝑛 = 415). The survival rates and
recurrence rate of patients who underwent LT or HR were
calculated from the date of operation.
Because this study was nonrandomized and observa-
tional, potential confounding selection bias was accounted
for with propensity score analysis. We computed the propen-
sityscore by usingmultiple logistic regressionwith the depen-
dent variable receiving HR or LT. The independent variables
were age, sex, Child-Pugh classification, tumor number,
tumor size, AFP, and DCP.We were able to match 40 patients
undergoing LT to 40 patients undergoing HR. For Kyoto
criteria patients, we match 23 patients undergoing LT to 23
patients undergoing HR. For the propensity score-matched
sample, patient characteristics of the HR and LT groups were
compared using McNemer’s test for binominal categorical
variables, Mantel’s 𝜒2 test for multinomial categorical vari-
ables, and paired 𝑡-test for continuous variables. For evalu-
ating the association between outcomes (survival and recur-
rence) and therapy (LT or HR), odds ratio was estimated by
using the conditional logistic regression. Cumulative overall
survival and recurrence rates were calculated using Kaplan-
Meier methods, and differences between curves were evalu-
ated using the log-rank test.
A 𝑃 value < 0.05 was considered significant. All statistical
data were generated using JMP 5.0.1 and SAS 9.2 (SAS
Institute, Cary, NC) and Prism 5 (GraphPad Software, Inc., La
Jolla, CA).
3. Results
Table 2 summarizes the baseline characteristics of the two
propensity score-matched groups. Both groups were well
balanced for all variables, including age, sex, the maximum
diameter of the tumor, number of tumors, DCP level, AFP
level, andChild-Pugh classification.Therewere no significant
differences in the baseline data between the groups. The
median follow-up time in the HR group and the LT group
was 87 months and 84 months, respectively.
The 1- and 5-year overall survival rates were 90% and
53% in the HR group and 82% and 63% in the LT group,
respectively. They were not significantly different between
the two therapies (𝑃 = 0.514) (Figure 1(a)). The odds ratio
using the propensity score-matched method was 0.842 (95%
confidence interval 0.433–1.638;𝑃 = 0.613). In contrast, the 1-
and 5-year recurrence rates were significantly lower in the LT
group (9% and 21%) than in the HR group (43% and 74%)
(𝑃 < 0.001) (Figure 1(b)).The odds ratio using the propensity
score-matched method was 0.214 (95% confidence interval
0.089–0.518; 𝑃 = 0.001).
Next, a similar analysis was performed in the 46
propensity-matched patients within our new expanded cri-
teria for LT for HCC (the Kyoto criteria). The baseline char-
acteristics of the two propensity-matched groups are shown
in Table 3. Both groups were well balanced for all variables,
including age, sex, the maximum diameter of the tumor,
number of tumors, DCP level, AFP level, and Child-Pugh
classification. The 1- and 5-year overall survival rates were
96% and 50% in the HR group and 82% and 68% in the LT
group, respectively. There were no significant differences
between the two therapies (𝑃 = 0.359) (Figure 2(a)). The
odds ratio was 0.727 (95% confidence interval 0.293–1.808;
4 Disease Markers
Table 3: Baseline characteristics of the two propensity-matched groups within the Kyoto criteria.
Characteristic LT (𝑛 = 23) HR (𝑛 = 23) 𝑃 value
Age (years) 58 (27–68)∗ 57 (42–69) 0.811
Sex (male/female) 15/8 15/8 1.000
Underlying liver disease 0.194
Viral hepatitis C 14 16
Viral hepatitis B 9 5
Others 0 2
Child-Pugh classification (A/B) 10/13 9/14 0.765
DCP 30 (5–266)∗ 44 (9–277)∗ 0.150
AFP 29 (3–28074)∗ 28 (3–1321)∗ 0.725
Maximum tumor size (cm) 1.8 (0.8–5.0) 2.1 (0.9–5.0) 0.349
Number of tumors 1 (1–5)∗ 1 (1–5)∗ 0.779
Milan criteria met 18 (78%) 21 (91%) 0.218
∗Data are given as median (range).
Tumor characteristics are those found on the preoperative imaging.
DCP, des-gamma-carboxy prothrombin; AFP, alpha-fetoprotein.























































Figure 1: Overall survival rates (a) and recurrence rates (b) in the HR and LT groups after adjustment with propensity scores in all patients.
HR, hepatic resection; LT, liver transplantation.
𝑃 = 0.493). In contrast, the 1- and 5-year recurrence rates
were significantly lower in the LT group (5% and 18%) than in
the HR group (31% and 74%) (𝑃 < 0.001) (Figure 2(b)). The
odds ratio was 0.200 (95% confidence interval 0.058–0.691;
𝑃 = 0.010).
The causes of death are quite different between the two
groups. In the HR group, 16 of 19 patients (84%) and 9 of
11 patients (82%) died of HCC recurrence in each propensity
score analysis. In contrast, only 4 of 16 (25%) and 2 of 8 (25%)
died of HCC recurrence in the LT group in each propen-
sity score analysis. Most of the remaining patients died of
noncancerous causes including sepsis and graft failure in the
early post-LT period.
4. Discussion
To the best of our knowledge, this study is the first to compare
outcomes between well-matched groups after HR and after
LDLT for HCC using Cox proportional hazards model
analysis at a single institution. It was clearly demonstrated
that patients who underwent LDLT had significantly lower
recurrence rates than those who underwent HR, while a
survival benefit could not be shown in the LDLT group. So
far, not a few studies have tried to compare outcomes after
HR and LT [21–27]. However, most studies have used a het-
erogeneous group of patients in relation to tumor burden, as
well as underlying liver dysfunction. In contrast, the present
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Figure 2: Overall survival rates (a) and recurrence rates (b) in the HR and LT groups after adjustment with propensity scores in patients
within the Kyoto criteria. HR, hepatic resection; LT, liver transplantation.
study compared survival and recurrence rates of HR versus
LT for HCC between well-matched groups, including Child-
Pugh classification, tumor number, tumor size, AFP, andDCP
levels. Dhir et al. recently conducted a meta-analysis of 10
published reports to compare survival outcomes after LT and
HR in patients with early HCC, namely, within theMilan cri-
teria, andwell-compensated cirrhosis [28].Themeta-analysis
of all 10 published studies revealed a survival advantage for LT
(odds ratio 0.581; 𝑃 = 0.027). However, analysis of intention-
to-treat studies only found no significant difference (odds
ratio 0.600; 𝑃 = 0.166). Most recently, Proneth et al. reported
that no survival advantage of LT could be found compared
with HR in a meta-analysis by use of seven studies with a
total of 1572 patients [29]. Taken together with these findings,
the survival advantage of LT is unclear, whereas LT evidently
offers a significantly better recurrence rate than HR.
LT is well known to have noteworthy advantages that HR
does not possess in the treatment of HCC. LT can treat not
only intrahepatic tumors but also underlying liver diseases.
On the other hand, LT has crucial disadvantages thatHRdoes
not have.The greatest disadvantage of LT is the relatively high
mortality in the early post-LT period. Lee et al. compared
early operative mortality in patients undergoing LT (𝑛 = 78)
and HR (𝑛 = 130) with HCC and underlying Child-Pugh A
or B cirrhosis [25]. They reported that the early operative
mortality rate was higher in the LT group (5.1%) than in the
HR group (0.8%), in line with our previous report that the
mortality rate in all patients who underwent LT in 2007 was
4.8% [30]. In the present study, the sharp decline of the sur-
vival curves in the LT group was shown in both well-matched
groups in all patients (Figure 1(a)) and in patients within
the Kyoto criteria (Figure 2(a)). In contrast with the HR
group, the major causes of death in the LT group were
noncancerous reasons including sepsis and graft failure, espe-
cially in the early post-LT period. However, recent advances
in perioperative management and technical innovations have
gradually decreased the in-hospital mortality rate. If themor-
tality risk after LT could be diminished to that after HR, the
overall survival rates in the LT group would become higher
than those in the HR group due to the low risk of HCC
recurrence. The next crucial disadvantage of LT is low organ
availability with both living and deceased donor LT. Donor
shortage is a common problem inWestern and Eastern coun-
tries. Moreover, the dropout rate while waiting for deceased
donor LT is not negligible. Literally, the total dropout rate at
12 months after listing for LT ranges from 11% to 30% [21, 31–
33]. These downsides associated with LT reduce its viability
as an alternative treatment option for patients with HCC.
In the present study, 46 propensity-matched patients
within our new expanded criteria for LT for HCC, the Kyoto
criteria, were further analyzed. The meta-analysis by Dhir
et al. examined patients with early HCC within the Milan
criteria only [28]. In contrast, this analysis included patients
with advanced HCC in size and tumor number. Interestingly,
LT showed significantly lower recurrence rates than HR even
in patients with more advanced HCC compared with the
Milan criteria, although no survival benefit was shown in this
subgroup analysis. We have so far reported the usefulness of
the Kyoto criteria as expanded selection criteria with a low
recurrence rate [9, 34, 35]. The important point of the
Kyoto criteria is incorporating DCP, a surrogate marker of
tumor aggressiveness, as a variable to exclude patients with a
high risk for recurrence preoperatively. Furthermore, the
findings of the current study support the usefulness of DCP.
Compared to our previous report that showed 5-year recur-
rence rates less than 5% in patients within the Kyoto criteria
[35], however, the 5-year recurrence rate of 18% in the LT
group in the present study is somewhat higher. Taking into
consideration the issue of organ shortage, HR might be the
first choice for these propensity-matched patients with HCC
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and underlying Child-Pugh A or B cirrhosis, in line with the
concept of salvage transplantation [36].
Some limitations must be borne in mind when consid-
ering this study. First, the patient number included in this
propensity-matched cohort was small, even though our insti-
tute is the largest LT center in Japan. In Japan, LT is usually
selected for patients with Child-Pugh classification C, while
HR is selected for patientswithChild-Pugh classificationAor
B. Moreover, patients with vascular invasion on preoperative
imaging were excluded from the study due to this being a
contraindication for LT. These factors led to small patient
numbers in the propensity-matched cohort. Therefore, a
multicenter, nationwide study is needed to confirm the
present findings. Second, the analysis used in this study was
not an intention-to-treat analysis. Dhir et al. emphasized that
patients who demonstrated disease progression while on the
waiting list and became unsuitable for transplantation or died
during waiting should be included to compare outcomes of
LT and HR in patients with HCC [28]. In the present study,
however, all patients in the LT group underwent LDLT,
resulting in quite a low dropout rate. Furthermore, 28 of
40 patients in the LT group had a history of pretreatment
including TACE, RFA, and HR. Moreover, patients in the
HR group also received TACE or RFA after HCC recurrence.
Strictly speaking, the survival rate after LT or HR for HCC
should be compared between patients with no history of
pretreatment and no postoperative treatment for recurrent
lesions. In other words, usual comparison of outcomes after
LT andHRdoes not exactly reflect the efficacies of LT andHR
themselves. To accurately compare outcomes after LT or
HR, a randomized, controlled study is needed; however, it is
actually impossible and not ethically appropriate. Therefore,
the propensity score-matching analysis used in the present
study could be an alternative to a randomized, controlled
study. Finally, the period of patient enrollment varied from
January 1999 to August 2012. Surgical techniques, periopera-
tive management, diagnostic imaging, and treatment modal-
ities for HCC recurrence have improved dramatically in
this decade for both HR and LT. Therefore, to exclude such
bias, we should compare patients who underwent each
surgical therapy over several years. In this context, a multi-
center, nationwide study would be better to obtain definite
conclusions.
5. Conclusions
LDLT can provide significantly better recurrence rates than
HR based on this propensity score-matching study in all
patients as well as those within our expanded selection crite-
ria incorporating biomarker for HCC, although no survival
benefit was seen in the LDLT group due to noncancerous
causes of death in the early post-LT period. Therefore, HR
should be considered a valid alternative to LDLT taking into
consideration the risk for the living donor at present. Efforts
to solve the problems associated with LT, including relatively
high post-transplantmortality andmorbidity rates and donor
shortages, are needed to take maximum advantage of the
merits of LDLT to improve the treatment of HCC.
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